Pfizer (PFE) Net Margin (2009 - 2026)

Pfizer has disclosed Net Margin across 18 years of filings, most recently posting 0.56% for Q1 2026.

• In Q1 2026, Net Margin changed N/A year-over-year to 0.56%; the TTM figure through Mar 2026 stood at 0.05% (up 2.0% YoY), while the FY2025 annual figure was 0.04%, down 9.0% from the prior year.
• Net Margin retreated to 0.56% in Q1 2026, from 1.1% in the prior quarter.
• Over the last five years, Net Margin for PFE reached as high as 1.1% in Q2 2025 and fell as low as 1.81% in Q3 2024.
• The 5-year median for Net Margin is 0.03% (2022), against an average of 0.1%.
• Annual changes were most pronounced in 2022 — Net Margin jumped 137 bps — and 2024, when it tumbled 254 bps.
• A 5-year view of Net Margin shows it stood at 0.09% in 2022, then sank by 716 bps to 0.76% in 2023, then tumbled by 139 bps to 1.81% in 2024, then surged by 161 bps to 1.1% in 2025, then slumped by 151 bps to 0.56% in 2026.
• According to Business Quant data, Net Margin over the past three periods registered 0.56%, 1.1%, and 1.81% for Q1 2026, Q2 2025, and Q3 2024 respectively.